References
- Doria A, Iaccarino L, Ghirardello A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006;119:700–706.
- Gatto M, Saccon F, Zen M, et al. Success and failure of biological treatment in systemic lupus erythematosus: a critical analysis. J Autoimmun. 2016;74:94–105.
- Schwarting A, Schroeder JO, Alexander T, et al. First real-world insights into belimumab use and outcomes in routine clinical care of systemic lupus erythematosus in Germany: results from the OBSErve Germany Study. Rheumatol Ther. 2016;3:271–290.
- Collins CE, Dall’Era M, Kan H, et al. Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA. Lupus Sci Med. 2016;3:e000118.
- Scheinberg M, de Melo FF, Bueno AN, et al. Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients. Clin Rheumatol. 2016;35:1719–1723.
- Iaccarino L, Bettio S, Reggia R, et al. Response to belimumab in SLE patients with high disease activity: data from a multicentric clinical-practice based study cohort [abstract]. Arthritis Rheumatol. 2016;68(suppl 10). Available from: http://acrabstracts.org/abstract/response-to-belimumab-in-sle-patients-with-high-disease-activity-data-from-a-multicentric-clinical-practice-based-study-cohort/.
- Iaccarino L, Bettio S, Reggia R, et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017;69:115–123.
- Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol. 2015;42:2288–2295.
- Andreoli L, Reggia R, Pea L, et al. Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients. Isr Med Assoc J. 2014;16:651–653.
- Scheinberg M, Golmia R. Real life experience on the effect of belimumab in patients with active systemic lupus. Springerplus. 2014;3:758.
- Specchia ML, de Waure C, Gualano ML, et al. Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus. Biomed Res Int. 2014;2014:1–9.
- Cortés J, Andreu JL, Calvo J, et al. Evaluation of use of belimumab in clinical practice settings (observe study) in Spain: health resource utilization and labour absenteeism. Value Health. 2014;17:A534.
- van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71:1343–1349.
- Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus, combined results from two phase III trials. Ann Rheum Dis. 2012;71:1833–1838.
- Zen M, Iaccarino L, Doria A, et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol. 2012;30:856–863.
- Bruce IN, Urowitz M, van Vollenhoven R, et al. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus. 2016;25:699–709.
- Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014;41:300–309.